234 related articles for article (PubMed ID: 9108353)
1. Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice.
van Beek ER; Löwik CW; Papapoulos SE
Bone; 1997 Apr; 20(4):335-40. PubMed ID: 9108353
[TBL] [Abstract][Full Text] [Related]
2. Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice.
Nijenhuis T; van der Eerden BC; Hoenderop JG; Weinans H; van Leeuwen JP; Bindels RJ
J Bone Miner Res; 2008 Nov; 23(11):1815-24. PubMed ID: 18597625
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
Van Beek ER; Löwik CW; Papapoulos SE
Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
[TBL] [Abstract][Full Text] [Related]
4. Alendronate reduces osteoclast precursors in osteoporosis.
D'Amelio P; Grimaldi A; Cristofaro MA; Ravazzoli M; Molinatti PA; Pescarmona GP; Isaia GC
Osteoporos Int; 2010 Oct; 21(10):1741-50. PubMed ID: 19949772
[TBL] [Abstract][Full Text] [Related]
5. In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis.
Most W; Schot L; Ederveen A; van der Wee-Pals L; Papapoulos S; Löwik C
J Bone Miner Res; 1995 Oct; 10(10):1523-30. PubMed ID: 8686508
[TBL] [Abstract][Full Text] [Related]
6. Effects of Alendronate and Dexamethasone on Osteoclast Gene Expression and Bone Resorption in Mouse Marrow Cultures.
de Faria LP; Sueyoshi G; de Oliveira TC; Holliday LS; Arana-Chavez VE
J Histochem Cytochem; 2022 Feb; 70(2):169-179. PubMed ID: 34915746
[TBL] [Abstract][Full Text] [Related]
7. Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo.
Endo Y; Nakamura M; Kikuchi T; Shinoda H; Takeda Y; Nitta Y; Kumagai K
Calcif Tissue Int; 1993 Mar; 52(3):248-54. PubMed ID: 8481841
[TBL] [Abstract][Full Text] [Related]
8. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Azuma Y; Sato H; Oue Y; Okabe K; Ohta T; Tsuchimoto M; Kiyoki M
Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053
[TBL] [Abstract][Full Text] [Related]
9. Colony stimulating factor-1 plays a role in osteoclast formation and function in bone resorption induced by parathyroid hormone and parathyroid hormone-related protein.
Weir EC; Lowik CW; Paliwal I; Insogna KL
J Bone Miner Res; 1996 Oct; 11(10):1474-81. PubMed ID: 8889847
[TBL] [Abstract][Full Text] [Related]
10. Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts.
Shu G; Yamamoto K; Nagashima M
Mod Rheumatol; 2006; 16(6):343-9. PubMed ID: 17164994
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage.
Orcel P; Denne MA; de Vernejoul MC
Endocrinology; 1991 Mar; 128(3):1638-46. PubMed ID: 1999178
[TBL] [Abstract][Full Text] [Related]
12. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Frith JC; Rogers MJ
J Bone Miner Res; 2003 Feb; 18(2):204-12. PubMed ID: 12568397
[TBL] [Abstract][Full Text] [Related]
13. Alendronate prevents cyclosporin A-induced osteopenia in the rat.
Sass DA; Bowman AR; Yuan Z; Ma Y; Jee WS; Epstein S
Bone; 1997 Jul; 21(1):65-70. PubMed ID: 9213009
[TBL] [Abstract][Full Text] [Related]
14. c-fos antisense DNA inhibits proliferation of osteoclast progenitors in osteoclast development but not macrophage differentiation in vitro.
Udagawa N; Chan J; Wada S; Findlay DM; Hamilton JA; Martin TJ
Bone; 1996 Jun; 18(6):511-6. PubMed ID: 8805990
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation.
Idris AI; Greig IR; Bassonga-Landao E; Ralston SH; van 't Hof RJ
Endocrinology; 2009 Jan; 150(1):5-13. PubMed ID: 18772231
[TBL] [Abstract][Full Text] [Related]
16. IL-1β differently stimulates proliferation and multinucleation of distinct mouse bone marrow osteoclast precursor subsets.
Cao Y; Jansen ID; Sprangers S; Stap J; Leenen PJ; Everts V; de Vries TJ
J Leukoc Biol; 2016 Sep; 100(3):513-23. PubMed ID: 26957213
[TBL] [Abstract][Full Text] [Related]
17. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis.
Frith JC; Mönkkönen J; Auriola S; Mönkkönen H; Rogers MJ
Arthritis Rheum; 2001 Sep; 44(9):2201-10. PubMed ID: 11592386
[TBL] [Abstract][Full Text] [Related]
18. Actin polymerization modulates CD44 surface expression, MMP-9 activation, and osteoclast function.
Samanna V; Ma T; Mak TW; Rogers M; Chellaiah MA
J Cell Physiol; 2007 Dec; 213(3):710-20. PubMed ID: 17508356
[TBL] [Abstract][Full Text] [Related]
19. Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis.
Hofkens W; Grevers LC; Walgreen B; de Vries TJ; Leenen PJ; Everts V; Storm G; van den Berg WB; van Lent PL
J Control Release; 2011 Jun; 152(3):363-9. PubMed ID: 21396411
[TBL] [Abstract][Full Text] [Related]
20. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders.
Murakami H; Takahashi N; Sasaki T; Udagawa N; Tanaka S; Nakamura I; Zhang D; Barbier A; Suda T
Bone; 1995 Aug; 17(2):137-44. PubMed ID: 8554921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
